Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.
about
Current issues in chronic graft-versus-host disease.CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease.Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host DiseaseAntibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice.Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.Classification systems for chronic graft-versus-host disease.Relationship between cytomegalovirus (CMV) reactivation, CMV-driven immunity, overall immune recovery and graft-versus-leukaemia effect in children.Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients.Treatment of refractory sclerodermatous chronic graft-versus-host disease with intravenous lidocaine infusions.
P2860
Q33917187-B5931FF3-AD51-4D22-9A4D-925C98244B51Q34311645-D402FD6A-1394-4B52-8670-3BC2F8FB1A9AQ35588726-C9185D27-523D-4AE4-A88B-7EA411CCD95FQ36220062-59AF4858-5DD4-4CB8-9920-68AA0ABE2DC6Q36876981-179975EA-A979-41C6-8635-C7B735786D79Q38202155-25FBF0FF-532E-445C-9B63-34FACABDC4CCQ38392246-A467F7C9-1BDA-445E-86FA-5F7FC75A546EQ39002161-77D2E212-2DF1-42DE-A788-B3A7ED4196EAQ42226854-69ED7DCA-69EC-4E52-BC70-85A0FA149076Q42258804-A2967453-C744-4CDE-91B1-50B1824FAFB6Q43745575-4A5DAC59-BB4C-4AA9-8497-BB8356C37275
P2860
Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Limited efficacy and tolerance ...... sclerodermatous chronic GVHD.
@en
Limited efficacy and tolerance ...... sclerodermatous chronic GVHD.
@nl
type
label
Limited efficacy and tolerance ...... sclerodermatous chronic GVHD.
@en
Limited efficacy and tolerance ...... sclerodermatous chronic GVHD.
@nl
prefLabel
Limited efficacy and tolerance ...... sclerodermatous chronic GVHD.
@en
Limited efficacy and tolerance ...... sclerodermatous chronic GVHD.
@nl
P2093
P50
P1433
P1476
Limited efficacy and tolerance ...... sclerodermatous chronic GVHD.
@en
P2093
Adèle de Masson
Aliénor Xhaard
Felipe Suarez
Jean-Baptiste Micol
Jean-David Bouaziz
Jean-Henri Bourhis
Jean-Hugues Dalle
Karima Yakouben
Lionel Adès
Marie Robin
P304
P356
10.1182/BLOOD-2012-09-453928
P407
P577
2012-12-01T00:00:00Z